期刊文献+

非小细胞肺癌中NUSAP1的表达及临床意义 被引量:11

Expression and clinical significance of NUSAP1 in non-small cell lung cancer
原文传递
导出
摘要 目的探讨非小细胞肺癌(NSCLC)组织中核仁纺锤体相关蛋白1(NUSAP1)的表达情况,分析其与患者临床病理特征的关系。方法收集新鲜NSCLC肿瘤组织及癌旁组织各10例,采用实时定量PCR和Western blot分别检测NUSAP1mRNA和蛋白的表达;另收集69例NSCLC患者手术切除的癌组织及癌旁组织,采用免疫组织化学染色检测NUSAP1的表达情况,并分析其表达与患者临床病理特征的关系。结果NSCLC组织中NUsAP1mRNA及蛋白表达均显著高于癌旁组织(t值分别为3.401、31.89,P值均〈0.05);NUSAP1在NSCLC组织中的高表达率为59.42%,而在癌旁组织中的高表达率为15.94%,差异有统计学意义(χ2=27.77,P〈0.05);NUSAP1在NSCLC组织中高表达与患者性别、年龄、TNM分期无关,但与肿瘤大小及有无淋巴结转移有关(χ2值分别为5.445、18.034,P值均〈0.05)。结论NUSAPI在NSCLC组织中呈异常高表达,可能与NSCLC的发生、发展相关。 Objective To investigate the expression and clinical significance of nucleolar and spindle-associated protein 1 (NUSAP1) in non-small cell lung cancer (NSCLC). Methods Ten cases of fresh NSCLC tissues and adjacent tissues were collected to detect the expressions of NUSAP1 mRNA and protein by quantitative real-time polymerase chain reaction and Western blot. 69 cases of NSCLC tissues and adjacent tissues were collected to detect the expression of NUSAP1 by immunohistochemical staining, and analyze the relationship between the expression of NUSAP1 and clinicopathological features of NSCLC. Results The expressions of NUSAP1 mRNA and protein in NSCLC tissues were significantly higher than those in adjacent tissues ( t = 3. 401, 31.89, all P % 0.05). The high expression rate of NUSAP1 was 59.42% in NSCLC tissues, and that was 15.94% in adjacent tissues, the difference was statistically significant ( χ2 =27.77, P〈0.05). NUSAP1 overexpression was not associated with gender, age and TNM stage, but was correlated with tumor size and lymphatic metastasis of NSCLC ( χ2=5. 445, 18. 034, all P 〈0.05). Conclusions NUSAP1 is overexpressed in NSCLC tissues and may be related to the occurrence and development of NSCLC.
出处 《国际呼吸杂志》 2017年第22期1681-1684,共4页 International Journal of Respiration
基金 科技部国际科技合作专项(2014DFA31940) 国家自然科学基金(81572259、81302011) 江苏省卫计委“科教强卫工程”医学青年人才项目(QNRC2016593) 江苏省医学重点学科(ZDXKA2016003)
关键词 非小细胞肺癌 核仁纺锤体相关蛋白1 临床病理特征 淋巴结转移 Non-small cell lung cancer Nucleolar and spindle-associated protein I Clinicopathologic characteristics Lymphatic metastasis
  • 相关文献

参考文献6

二级参考文献78

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1368
  • 2黄健,王茂生,梁宇强.肺癌淋巴结转移特点及转移方式的临床分析[J].中国医师杂志,2006,8(2):168-170. 被引量:6
  • 3马毅,何晓顺,陈规划.肝癌肝移植术后肿瘤的复发及有效干预研究进展[J].中华实验外科杂志,2007,24(2):254-256. 被引量:12
  • 4Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CA CancerJ Clin, 2012, 62(1):10-29.
  • 5Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study[J]. Lancet Oncol, 2010, 11(6):521-529.
  • 6Mok TS, Wu YL, Yhongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma[J]. N EnglJ Med, 2009, 361 (10) :947-957.
  • 7Rosell R, Garcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as ftrst--line treatment for European patients with advanced EGFR mutation positive non- small- ceU lung cancer (EURTAG): a muhicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(3):239-246.
  • 8Shi YK, Zhang L, Liu XOx et al. Icotinib versus gefitinib in previously treated advanced non-small-ceU lung cancer (ICOGEN): a ran- domized, doubleblind phase 3 non-inferiority trial[J]. Lancet Oncol, 2013, 14(10):953-961.
  • 9Miller VA, Hirsh V, CadranelJ, et al. Afafinib versus placebo for patients with advanced, metastatic non-smaU-cell lung cancer af- ter failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised tria[J]. Lancet Oncol, 2012, 13(5):528-538.
  • 10Janne PA, Ou SH, Kim DW, et al. Dacomitinib as ftrst-line treat- ment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trialm. Lancet Oncol, 2014, 15(13):1433-1441.

共引文献63

同被引文献65

引证文献11

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部